Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phenelzine Sulfate and Abraxane in Metastatic Breast Cancer
NCT03505528Phase 1Completed
- Sponsor
- EpiAxis Therapeutics
- Start
- Aug 2017
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of phenelzine in breast cancer, sponsored by EpiAxis Therapeutics. Primary endpoint: Dose-Limiting Toxicity at 56 days. Started Aug 2017; status: completed.
02
Drugs
phenelzine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03505528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03505528.